Molecular genetic features of meningiomas

Close metadata

Recommended articles:

Accessory nerve meningioma. A case report and literature review. Burdenko's Journal of Neurosurgery. 2024;(3):90-95

En plaque convexity hyperostotic meningioma: 69 cases from a singlecenter. Burdenko's Journal of Neurosurgery. 2025;(1):20-29

Sellar collision tumors: difficulties of preoperative neuroimaging and selection of surgical approach. Case reports and literature review. Burdenko's Journal of Neurosurgery. 2025;(3):75-82

Metastatic meningiomas: a case series and literature review. Burdenko's Journal of Neurosurgery. 2025;(3):83-91

Drug therapy for locally advanced and metastatic non-small cell lung cancer with MET mutation: indirect comparison. Medical Technologies. Assessment and Choice. 2024;(3):82-92

New pathogenic treatments for myasthenia gravis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):31-38

Clinical significance of genetic mutations in epithelial tumors of the thymus. P.A. Herzen Journal of Oncology. 2025;(2):70-75

Meningioma is the most common primary tumor of the central nervous system. Traditional classification is based on histological properties of tumors and distinguishes different grades of meningioma malignancy. However, knowledge about different molecular mechanisms of tumor provided new data on genetic features of meningiomas. The authors analyze current available data on the main driver mutations, new classifications based on molecular genetic characteristics and potential targets for therapy.

Keywords:

meningioma

Nf2

TERT

targeted therapy

Authors:

Makashova E.S.

Burdenko Neurosurgical Center;
Loginov Moscow Clinical Scientific Practical Center

Lasunin N.V.

Burdenko Neurosurgical Center

ORCID: 0000-0002-6169-4929

Galkin M.V.

Burdenko National Medical Research Center for Neurosurgery

SPIN RSCI: 7745-6695
Scopus AuthorID: 36099071200
ResearcherID: AAH-4783-2019
ORCID: 0000-0002-1436-0010

Zolotova S.V.

Burdenko Neurosurgical Center

ORCID: 0000-0001-8893-3830

Karandasheva K.O.

Bochkov Medical Genetic Research Center

ORCID: 0000-0003-2919-9458

Golanov A.V.

Burdenko Neurosurgical Center

ORCID: 0000-0002-0976-4547

Received:

01.12.2022

Accepted:

19.05.2023

List of references:

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231-1251. https://doi.org/10.1093/neuonc/noab106
Young IM, Yeung J, Glenn C, Teo C, Sughrue ME. Aggressive Progression of a WHO Grade I Meningioma of the Posterior Clinoid Process: An Illustration of the Risks Associated With Observation of Skull Base Meningiomas. Cureus. 2021;13(3):e14005. https://doi.org/10.7759/cureus.14005
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi WL. A molecularly integrated grade for meningioma. Neuro-Oncology. 2022;24(5):796-808. https://doi.org/10.1093/neuonc/noab213
Lee S, Karas PJ, Hadley CC, Bayley V JC, Khan AB, Jalali A, Sweeney AD, Klisch TJ, Patel AJ. The Role of Merlin/NF2 Loss in Meningioma Biology. Cancers. 2019;11(11):1633. https://doi.org/10.3390/cancers11111633
Lee YS, Lee YS. Molecular characteristics of meningiomas. Journal of Pathology and Translational Medicine. 2020;54(1):45-63. https://doi.org/10.4132/jptm.2019.11.05
Ahrendsen JT, Hsu N, Wolf Z, Bryke C, Varma H. Multiple Whole Chromosomal Gains Define Angiomatous Meningiomas and Are Absent From the Tumor Vasculature. Journal of Neuropathology & Experimental Neurology. 2020;79(6):618-625. https://doi.org/10.1093/jnen/nlaa031
Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proceedings of the National Academy of Sciences. 1997;94(26):14719-24. https://doi.org/10.1073/pnas.94.26.14719
Lamszus K. Meningioma pathology, genetics, and biology. Journal of Neuropathology and Experimental Neurology. 2004;63(4):275-86. https://doi.org/10.1093/jnen/63.4.275
Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, Ducar M, Thorner AR, van Hummelen P, Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R. Genomic landscape of high-grade meningiomas. NPJ Genomic Medicine. 2017;2:15. https://doi.org/10.1038/s41525-017-0014-7
Paramasivam N, Hübschmann D, Toprak UH, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers AK, Jones DTW, Gu Z, Werner J, Uhrig S, Wirsching HG, Schick M, Bewerunge-Hudler M, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister SM, Wick W, Weller M, Grossmann R, von Deimling A, Schlesner M, Sahm F. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathology. 2019;138(2):295-308. https://doi.org/10.1007/s00401-019-02008-w
Begnami MD, Palau M, Rushing EJ, Santi M, Quezado M. Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. Human Pathology. 2007;38(9):1345-1350. https://doi.org/10.1016/j.humpath.2007.01.027
Teranishi Y, Okano A, Miyawaki S, Ohara K, Ishigami D, Hongo H, Dofuku S, Takami H, Mitsui J, Ikemura M, Komura D, Katoh H, Ushiku T, Ishikawa S, Shin M, Nakatomi H, Saito N. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index. Acta Neuropathologica Communications. 2022;10(1):76. https://doi.org/10.1186/s40478-022-01377-w
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kiliç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077-1080. https://doi.org/10.1126/science.1233009
Karsy M, Azab MA, Abou-Al-Shaar H, Guan J, Eli I, Jensen RL, Ormond DR. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons. Neurosurgical Focus. 2018;44(6):10. https://doi.org/10.3171/2018.2.FOCUS1849
Zotti T, Scudiero I, Vito P, Stilo R. The Emerging Role of TRAF7 in Tumor Development. Journal of Cellular Physiology. 2017;232(6):1233-1238. https://doi.org/10.1002/jcp.25676
Proctor DT, Ramachandran S, Lama S, Sutherland GR. Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms. World Neurosurgery. 2018;119:366-373. https://doi.org/10.1016/j.wneu.2018.08.019
Preusser M, Brastianos PK, Mawrin C. Advances in meningioma genetics: novel therapeutic opportunities. Nature Reviews Neurology. 2018;14(2):106-115. https://doi.org/10.1038/nrneurol.2017.168
Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Kessler AF, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A. TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute. 2015;108(5):djv377. https://doi.org/10.1093/jnci/djv377
Pereira BJA, Oba-Shinjo SM, de Almeida AN, Marie SKN. Molecular alterations in meningiomas: Literature review. Clinical Neurology and Neurosurgery. 2019;176:89-96. https://doi.org/10.1016/j.clineuro.2018.12.004
Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncology. 2016;18(5):649-655. https://doi.org/10.1093/neuonc/nov316
Aizer AA, Abedalthagafi M, Bi WL, Horvath MC, Arvold ND, Al-Mefty O, Lee EQ, Nayak L, Rinne ML, Norden AD, Reardon DA, Wen PY, Ligon KL, Ligon AH, Beroukhim R, Dunn IF, Santagata S, Alexander BM. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-Oncology. 2016;18(2):269-274. https://doi.org/10.1093/neuonc/nov177
Di Cristofori A, Del Bene M, Locatelli M, Boggio F, Ercoli G, Ferrero S, Del Gobbo A. Meningioma and Bone Hyperostosis: Expression of Bone Stimulating Factors and Review of the Literature. World Neurosurgery. 2018;115: 774-781. https://doi.org/10.1016/j.wneu.2018.04.176
Rahner N, Steinke V. Hereditary cancer syndromes. Deutsches Ärzteblatt international. 2008;105(41):706-714. https://doi.org/10.3238/arztebl.2008.0706
Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Wolkenstein P, Evans DG. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine. 2022;24(9):1967-1977. https://doi.org/10.1016/j.gim.2022.05.007
Lipsick J. A History of Cancer Research: Tumor Suppressor Genes. Cold Spring Harbor Perspectives in Biology. 2020;12(2):a035907. https://doi.org/10.1101/cshperspect.a035907
Schraepen C, Donkersloot P, Duyvendak W, Plazier M, Put E, Roosen G, Vanvolsem S, Wissels M, Bamps S. What to know about schwannomatosis: a literature review. British Journal of Neurosurgery. 2022;36(2):171-174. https://doi.org/10.1080/02688697.2020.1836323
Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. Journal of Neuro-Oncology. 2010;99(3):341-347. https://doi.org/10.1007/s11060-010-0339-x
Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120-128. https://doi.org/10.1016/j.gene.2019.02.076
Yakubov E, Ghoochani A, Buslei R, Buchfelder M, Eyüpoglu IY, Savaskan N. Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency. Oncoscience. 2016;3(5-6):149-155. https://doi.org/10.18632/oncoscience.305
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G. Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discovery. 2020;10(8):1103-1120. https://doi.org/10.1158/2159-8290.CD-19-1220
Kerr K, Qualmann K, Esquenazi Y, Hagan J, Kim DH. Familial Syndromes Involving Meningiomas Provide Mechanistic Insight Into Sporadic Disease. Neurosurgery. 2018;83(6):1107-1118. https://doi.org/10.1093/neuros/nyy121
Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R, Macklin AM, Khan S, Singh O, Karimi S, Corona RI, Liu LY, Chen CY, Chakravarthy A, Wei Q, Mehani B, Suppiah S, Gao A, Workewych AM, Tabatabai G, Boutros PC, Bader GD, de Carvalho DD, Kislinger T, Aldape K, Zadeh G. A clinically applicable integrative molecular classification of meningiomas. Nature. 2021;597(7874):119-125. https://doi.org/10.1038/s41586-021-03850-3
Weller M, Roth P, Sahm F, Burghardt I, Schuknecht B, Rushing EJ, Regli L, Lindemann JP, von Deimling A. Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. Journal of the National Cancer Institute. 2017;109(3):1-4. https://doi.org/10.1093/jnci/djw320
Mathew Thomas V, Bindal P, Vredenburgh JJ. Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma. Case Reports in Oncology. 2019;12(1):126-130. https://doi.org/10.1159/000496984
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clinical Cancer Research. 2020;26(3):552-557. https://doi.org/10.1158/1078-0432.CCR-19-2109
Birzu C, Peyre M, Sahm F. Molecular alterations in meningioma: prognostic and therapeutic perspectives. Current Opinion in Oncology. 2020;32(6):613-622. https://doi.org/10.1097/CCO.0000000000000687
Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Ansstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG 2nd, Galanis E. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. Journal of Clinical Oncology. 2023;41(3):618-628. https://doi.org/10.1200/JCO.21.02371

Close metadata